Polycystic Liver Disease Clinical Trial
Official title:
Single Center, Open-label Randomized Prospective Trial: Effect of Sirolimus on Polycystic Liver Disease
The purpose of this study is to see if one kind of immunosuppressive drug has better effects for the patient's polycystic liver disease than another type. Tacrolimus and Sirolimus are the two immunosuppressive drugs that will be compared for this study. Both drugs have been commonly prescribed to prevent rejection.
Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease
with a prevalence of 1 in 400-1000 livebirths. ADPKD is caused by mutations to polycystic
kidney disease 1 gene (PKD1) (approximately 85% of cases) or polycystic kidney disease 2
gene (PKD2) (the remaining 15%) gene, encoding polycystin-1 (PC1) and polycystin-2 (PC2),
respectively. PC1 is a putative cell-surface, receptor-like protein with yet
to-be-identified ligand(s), and PC2 a channel protein with a high conductance to Ca2+.
Polycystic liver disease (PLD) is the most common extra-renal manifestation in ADPKD,
present in > 90% of ADPKD patients by age 30. Liver cysts in ADPKD originate from biliary
micro-hamartoma or focal proliferations of biliary ductules and from peribiliary glands.
Excessive proliferation of biliary epithelial cells, combined with neovascularization,
altered cell-extracellular matrix (ECM) interaction/ECM remodeling and cAMP-mediated fluid
secretion, is required for the development and expansion of PLD liver cysts.
PLD may become symptomatic with acute complications such as cyst hemorrhage, rupture and
infection. Chronic symptoms are frequently associated with massively enlarged PLD, including
abdominal distension and pain; dyspnea; gastroesophageal reflux and early satiety which may
lead to malnutrition; mechanical lower back pain; obstruction of the inferior vena cava,
hepatic and portal veins (leading to dialysis-associated hypotension, hepatic venous outflow
obstruction, and portal hypertension) and biliary obstruction. Currently, apart from
invasive interventions such as cyst aspiration with sclerosis, cyst fenestration combined
hepatic resection and cyst fenestration, liver transplantation and, rarely, selective
hepatic artery embolization, no medical therapy is available.
The objective of this study is to conduct a prospective, open-label, randomized trial to
examine the effect of sirolimus on total liver volume in kidney transplant recipients with
ADPKD.
Four weeks following kidney transplant, subjects will undergo iothalamate clearance
measurement, 24-hour urine collection and protein measurement and physical examination by a
transplant surgeon. Patients will be randomized to receive either sirolimus-based
immunosuppression or to continue tacrolimus-based immunosuppression unless one of the
following conditions are noted:
1. Complications of the kidney transplant incision, including, but not limited to:
superficial wound infection, deep wound infection, and fascial dehiscence
2. Iothalamate clearance measurement less than 40 mL/min/1.72m^2
3. Urinary protein excretion greater than 800 mg/24 hours. Subjects with the above
conditions will continue to receive tacrolimus-based immunosuppression at the
discretion of the treating physician/surgeon.
Enrolled subjects will undergo abdominal and pelvic CT scans within 3 months before or after
kidney transplantation and at one, two, and three years after kidney transplantation.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05215964 -
The Association Between Skeletal Muscle Mass and Severity of Polycystic Liver Disease and Polycystic Kidney Disease
|
||
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Recruiting |
NCT05500157 -
Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts
|
N/A | |
Completed |
NCT01354405 -
Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)
|
N/A | |
Completed |
NCT01315795 -
Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05281328 -
A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD
|
Phase 2/Phase 3 | |
Recruiting |
NCT02173080 -
Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).
|
||
Completed |
NCT01157858 -
Everolimus and LongActing Octreotide Trial in Polycystic Livers
|
Phase 2 | |
Recruiting |
NCT05478083 -
A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease
|
Phase 2 | |
Recruiting |
NCT04645251 -
Polycystic Liver Disease Registry (UK)
|
||
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Completed |
NCT02021110 -
Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease
|
Phase 2 | |
Completed |
NCT01670110 -
Pasireotide LAR in Severe Polycystic Liver Disease
|
Phase 2 | |
Active, not recruiting |
NCT00771888 -
Open-Label Extension of LOCKCYST Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT03960710 -
Automatic Segmentation of Polycystic Liver
|